SPRR2A and inflammatory bowel disease: Before its introduction, only anti-TNF (Infliximab, Adalimumab), anti-integrin (Vedolizumab), and anti-interleukin (IL)-12/23 (Ustekinumab) molecules were used as biological agents in IBD patients.